Search results
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by UBS Group
ETF DAILY NEWS· 5 days agoZentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) was downgraded by UBS Group from a “buy” rating to a “neutral” rating in a report issued on Thursday, Briefing.com reports. UBS Group ...
IgG4-Related Disease Affects Men More Often, More Severely
Medscape· 5 days agoA recent study highlighted sex-based differences in manifestations of IgG4-related disease.
Wells Fargo & Company Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Equal Weight
ETF DAILY NEWS· 7 days agoWells Fargo & Company downgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) from an overweight rating to an equal weight rating in a research report report published on Tuesday ...
Oppenheimer Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $25.00
ETF DAILY NEWS· 7 days agoZentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price objective trimmed by Oppenheimer from $50.00 to $25.00 in a report issued on Tuesday morning, Benzinga reports. Wells Fargo ...
Zentalis Pharmaceuticals’ (ZNTL) “Equal Weight” Rating Reaffirmed at Morgan Stanley
ETF DAILY NEWS· 7 days agoMorgan Stanley restated their equal weight rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) in a research note published on Tuesday morning, MarketBeat reports. Other ...
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wedbush
ETF DAILY NEWS· 7 days agoWedbush downgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) from a neutral rating to an underperform rating in a research report sent to investors on Tuesday morning, MarketBeat ...
Zentalis Pharmaceuticals’ (ZNTL) “Hold” Rating Reaffirmed at Jefferies Financial Group
ETF DAILY NEWS· 7 days agoJefferies Financial Group restated their hold rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) in a research report released on Tuesday morning, MarketBeat.com reports ...
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $10.00 by Analysts at Stifel Nicolaus
ETF DAILY NEWS· 7 days agoZentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price objective reduced by Stifel Nicolaus from $32.00 to $10.00 in a research report report published on Tuesday morning, Benzinga ...
Zentalis Pharmaceuticals (NASDAQ:ZNTL) PT Lowered to $20.00 at HC Wainwright
ETF DAILY NEWS· 7 days agoZentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price objective cut by HC Wainwright from $40.00 to $20.00 in a report issued on Tuesday morning, Benzinga reports. Stifel Nicolaus ...
Ceftazidime is a potential drug to inhibit cell proliferation by increasing cellular p27 - The...
Nature· 6 days agoThe development of new therapeutic uses for existing drugs is important for the treatment of some diseases. Cephalosporin antibiotics stand as the most extensively utilized ...